Anastrozole
NDC Package 62175-710-32

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Anastrozole is used to treat breast cancer in women after menopause. Marketed by Lannett Company, Inc., this product is identified by NDC 62175-710 and is authorized under FDA application ANDA091331.

Identification & Billing

NDC Package Code
62175-710-32
Package Description
30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
62175071032

Clinical Specifications

Proprietary Name
Anastrozole
Dosage Form
-
Usage Information
Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Regulatory & Marketing

Labeler Name
Lannett Company, Inc.
FDA Application #
ANDA091331
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-05-2011
End Marketing Date
09-22-2022
Listing Expiration
09-22-2022
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62175-710-32 identifies a specific commercial package of 30 tablet, film coated in 1 bottle, plastic of Anastrozole, labeled by Lannett Company, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Lannett Company, Inc. on January 05, 2011. The current certification is valid through September 22, 2022.

What are the primary indications for this medication?

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

How is this Lannett Company, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62175071032. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62175-710-32
11-Digit CMS (5-4-2)
62175-0710-32

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.